Pediatrix Medical Group, Inc. (NYSE:MD) Stock Has Consensus Price Target of $26.60 According to Analysts

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have been assigned an average recommendation of “Hold” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $26.60.

Several analysts recently commented on the stock. Weiss Ratings raised shares of Pediatrix Medical Group from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, September 9th. UBS Group increased their target price on Pediatrix Medical Group from $25.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, August 6th. Truist Financial lifted their target price on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the company a “hold” rating in a research report on Tuesday, July 14th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $25.00 target price on shares of Pediatrix Medical Group in a report on Wednesday, August 5th. Finally, Wall Street Zen upgraded shares of Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 13th.

Pediatrix Medical Group Stock Performance

Shares of MD opened at $25.66 on Friday. Pediatrix Medical Group has a 1 year low of $15.69 and a 1 year high of $27.94. The company’s 50 day simple moving average is $26.39 and its 200 day simple moving average is $24.02. The company has a market capitalization of $2.08 billion, a price-to-earnings ratio of 12.28 and a beta of 0.64. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.32.

Pediatrix Medical Group (NYSE:MD) last announced its earnings results on Tuesday, August 4th. The company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%.The business had revenue of $487.78 million for the quarter, compared to the consensus estimate of $478.49 million. During the same period last year, the business posted $0.53 EPS. The company’s revenue was up 4.1% on a year-over-year basis. On average, sell-side analysts predict that Pediatrix Medical Group will post 2.17 EPS for the current year.

Institutional Trading of Pediatrix Medical Group

Several hedge funds and other institutional investors have recently bought and sold shares of MD. Global Retirement Partners LLC bought a new stake in shares of Pediatrix Medical Group during the 2nd quarter valued at approximately $33,000. Nykredit A S bought a new position in shares of Pediatrix Medical Group during the 2nd quarter worth about $35,000. Eurizon Capital SGR S.p.A. acquired a new position in Pediatrix Medical Group during the fourth quarter worth $33,000. Integrated Wealth Concepts LLC bought a new position in shares of Pediatrix Medical Group in the second quarter valued at approximately $53,000. Finally, Public Employees Retirement System of Ohio bought a new stake in Pediatrix Medical Group in the 2nd quarter worth about $63,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc is a physician-led healthcare services company that provides specialized medical care for women, infants and children. The company partners with hospitals and health systems to deliver care through physician practices, neonatal intensive care units and other hospital-based programs.

Its services include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric hospital medicine and other pediatric subspecialties. Pediatrix physicians care for patients before, during and after childbirth, as well as children requiring specialized or critical care.